Physician profile

John William Shook

Surgical Oncology · Kansas City, MO

NPI 1215976915

$3,993.84

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$800.00
Travel and Lodging$646.65
Food and Beverage$374.78

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Molli Surgical (US) INC $2,192.07 2022-2023
Medtronic USA, INC. $851.08 2019
Hologic INC $636.69 2023 Biozorb, Localizer
W. L. Gore & Associates, INC. $140.83 2022
Endomagnetics LTD $135.91 2024 Magtrace, Magseed
Sirius Medical Systems $24.00 2023 Pintuition
Hologic Sales and Service, LLC $13.26 2024 Localizer, Trunode

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John William Shook

$3,993.84

in general payments reported 2019-2025

Years
2019-2024
Top company
Molli Surgical (US) INC

https://glasscript.com/doctor/483540/john-william-shook

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.